Cargando…
Novel Targeted Therapy for Neuroblastoma: Silencing the MXD3 Gene Using siRNA
BACKGROUND: Neuroblastoma is the second most common extracranial cancer in children. Current therapies for neuroblastoma, which use a combination of chemotherapy drugs, have limitations for high-risk subtypes and can cause significant long-term adverse effects in young patients. Therefore, a new the...
Autores principales: | Duong, Connie, Yoshida, Sakiko, Chen, Cathy, Barisone, Gustavo, Diaz, Elva, Li, Yueju, Beckett, Laurel, Chung, Jong, Antony, Reuben, Nolta, Jan, Nitin, Nitin, Satake, Noriko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5766270/ https://www.ncbi.nlm.nih.gov/pubmed/28419087 http://dx.doi.org/10.1038/pr.2017.74 |
Ejemplares similares
-
MXD3 regulation of DAOY cell proliferation dictated by time course of activation
por: Ngo, Tin, et al.
Publicado: (2014) -
Role of MXD3 in Proliferation of DAOY Human Medulloblastoma Cells
por: Barisone, Gustavo A., et al.
Publicado: (2012) -
Alternative Splicing of MXD3 and Its Regulation of MXD3 Levels in Glioblastoma
por: Ngo, Tin, et al.
Publicado: (2019) -
A distinct subpopulation of leukemia initiating cells in acute precursor B lymphoblastic leukemia: quiescent phenotype and unique transcriptomic profile
por: Lee, Alex Q., et al.
Publicado: (2022) -
Therapeutic siRNA silencing in inflammatory monocytes
por: Leuschner, Florian, et al.
Publicado: (2011)